Sol-Gel Technologies (SLGL) Short term Debt (2016 - 2017)
Sol-Gel Technologies (SLGL) posted quarterly Short term Debt of $65.3 million for Q4 2017, up 74.99% year-over-year from $37.3 million in Q4 2016, and up 74.99% quarter-over-quarter from $37.3 million in Q4 2016.
Powered by 
Analysis
Sol-Gel Technologies (SLGL) Short term Debt (2016 - 2017) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Short term Debt for 2 consecutive years, with $65.3 million the latest figure, recorded in Q4 2017.
- In Q4 2017, Short term Debt rose 74.99% year-over-year to $65.3 million; the TTM figure through Dec 2017 stood at $65.3 million (up 74.99% YoY), while the FY2017 annual figure was $65.3 million, up 74.99% from the prior year.
- Short term Debt rose to $65.3 million in Q4 2017 per SLGL's latest filing, from $37.3 million in the prior quarter.
- Across five years, Short term Debt topped out at $65.3 million in Q4 2017 and bottomed at $37.3 million in Q4 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Sol-Gel Technologies | 194.01 Mn | 146.08 Mn | - |